A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regimen every two months for treatment of HIV-1 in adults who have not previously taken antiretroviral therapy.

You likely can't join if

• • Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
• • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
• • Participants who, in the Investigator's judgment, pose a significant suicide risk. Participant’s recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
• • Signs and symptoms which, in the opinion of the Investigator, are suggestive of active SARS-CoV-2 infection within 14 days prior to enrolment.
• • Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded. Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor. Participants who completed treatment at least 7 days prior to Screening are eligible.
• • Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to first dose of study treatment.